Literature DB >> 22902506

2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer.

Ping Ma1, S Rahima Benhabbour, Lan Feng, Russell J Mumper.   

Abstract

The aim of these studies was to develop a novel 2'-behenoyl-paclitaxel (C22-PX) conjugate nanoparticle (NP) formulation for the treatment of metastatic breast cancer. A lipophilic paclitaxel derivative C22-PX was synthesized and incorporated into lipid-based NPs. Free C22-PX and its NP formulation were evaluated in a series of in vitro and in vivo studies. The results demonstrated that C22-PX NPs were much better tolerated and had significantly higher plasma and tumor AUCs compared to Taxol at the maximum tolerated dose (MTD) in a subcutaneous 4T1 mouse mammary carcinoma model. These benefits resulted in significantly improved antitumor efficacy with the NP-based formulation.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22902506      PMCID： PMC3522796          DOI： 10.1016/j.canlet.2012.08.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  32 in total

1.  A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: design and synthesis of isotaxel.

Authors:  Yoshio Hayashi; Mariusz Skwarczynski; Yoshio Hamada; Youhei Sohma; Tooru Kimura; Yoshiaki Kiso
Journal:  J Med Chem       Date:  2003-08-28       Impact factor: 7.446

Review 2.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

3.  Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.

Authors:  M O Bradley; N L Webb; F H Anthony; P Devanesan; P A Witman; S Hemamalini; M C Chander; S D Baker; L He; S B Horwitz; C S Swindell
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

Review 4.  Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

Authors:  H Gelderblom; J Verweij; K Nooter; A Sparreboom
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

5.  Hydrolyzable hydrophobic taxanes: synthesis and anti-cancer activities.

Authors:  S Ali; I Ahmad; A Peters; G Masters; S Minchey; A Janoff; E Mayhew
Journal:  Anticancer Drugs       Date:  2001-02       Impact factor: 2.248

6.  Tumor targeting by conjugation of DHA to paclitaxel.

Authors:  M O Bradley; C S Swindell; F H Anthony; P A Witman; P Devanesan; N L Webb; S D Baker; A C Wolff; R C Donehower
Journal:  J Control Release       Date:  2001-07-06       Impact factor: 9.776

7.  The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice.

Authors:  James M Gallo; Shaolan Li; Ping Guo; Karin Reed; Jianguo Ma
Journal:  Cancer Res       Date:  2003-08-15       Impact factor: 12.701

8.  A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration.

Authors:  B B Lundberg; V Risovic; M Ramaswamy; K M Wasan
Journal:  J Control Release       Date:  2003-01-09       Impact factor: 9.776

9.  Synthesis and evaluation of water-soluble paclitaxel prodrugs.

Authors:  Xia Feng; Ying-Jin Yuan; Jin-Chuan Wu
Journal:  Bioorg Med Chem Lett       Date:  2002-11-18       Impact factor: 2.823

10.  Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours.

Authors:  M Harries; A O'Donnell; M Scurr; S Reade; C Cole; I Judson; A Greystoke; C Twelves; S Kaye
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640
View more
  17 in total

Review 1.  Lipid-Drug Conjugate for Enhancing Drug Delivery.

Authors:  Danielle Irby; Chengan Du; Feng Li
Journal:  Mol Pharm       Date:  2017-01-24       Impact factor: 4.939

Review 2.  Nanoparticles for imaging and treatment of metastatic breast cancer.

Authors:  Qingxin Mu; Hui Wang; Miqin Zhang
Journal:  Expert Opin Drug Deliv       Date:  2016-07-19       Impact factor: 6.648

3.  Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles.

Authors:  Feng Li; Candace Snow-Davis; Chengan Du; Mikhail L Bondarev; Marilyn D Saulsbury; Simone O Heyliger
Journal:  J Vis Exp       Date:  2016-08-02       Impact factor: 1.355

4.  In vivo Serum Enabled Production of Ultrafine Nanotherapeutics for Cancer Treatment.

Authors:  Qingxin Mu; Guanyou Lin; Zachary R Stephen; Steve Chung; Hui Wang; Victoria K Patton; Rachel N Gebhart; Miqin Zhang
Journal:  Mater Today (Kidlington)       Date:  2020-05-04       Impact factor: 31.041

5.  Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT).

Authors:  Andrew J Madden; Sumit Rawal; Katie Sandison; Ryan Schell; Allison Schorzman; Allison Deal; Lan Feng; Ping Ma; Russell Mumper; Joseph DeSimone; William C Zamboni
Journal:  J Nanopart Res       Date:  2014-11-01       Impact factor: 2.253

6.  Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review.

Authors:  Ping Ma; Russell J Mumper
Journal:  Nano Today       Date:  2013-06-01       Impact factor: 20.722

7.  Rapid microwave-assisted synthesis of sub-30nm lipid nanoparticles.

Authors:  Stuart S Dunn; Denis R Beckford Vera; S Rahima Benhabbour; Matthew C Parrott
Journal:  J Colloid Interface Sci       Date:  2016-11-02       Impact factor: 8.128

Review 8.  Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.

Authors:  Andrew T Lucas; Lauren Sl Price; Allison Schorzman; William C Zamboni
Journal:  Nanomedicine (Lond)       Date:  2017-07-26       Impact factor: 5.307

9.  Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicity.

Authors:  Kevin S Chu; Mathew C Finniss; Allison N Schorzman; Jennifer L Kuijer; J Christopher Luft; Charles J Bowerman; Mary E Napier; Zishan A Haroon; William C Zamboni; Joseph M DeSimone
Journal:  Nano Lett       Date:  2014-02-24       Impact factor: 11.189

10.  Paclitaxel Nano-Delivery Systems: A Comprehensive Review.

Authors:  Ping Ma; Russell J Mumper
Journal:  J Nanomed Nanotechnol       Date:  2013-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.